Skip to main content

Kesimpta Side Effects

Generic name: ofatumumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jul 28, 2023.

Note: This document contains side effect information about ofatumumab. Some dosage forms listed on this page may not apply to the brand name Kesimpta.

Applies to ofatumumab: solution.

Warning

Intravenous route (Solution)

Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab.

Serious side effects of Kesimpta

Along with its needed effects, ofatumumab (the active ingredient contained in Kesimpta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ofatumumab:

More common

Less common

Incidence not known

Check with your doctor immediately if any of the following side effects occur while taking ofatumumab:

More common

Other side effects of Kesimpta

Some side effects of ofatumumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Pharmaceutical Society of Australia. APPGuide online. Australian prescription products guide online. http://www.appco.com.au/appguide/default.asp 2006.

3. Product Information. Arzerra (ofatumumab). GlaxoSmithKline. 2009.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.